Stefan Russmann1,2,3,4, Ali Rahmany5,6,7, David Niedrig5,8, Karl-Dietrich Hatz9, Katja Ludin10, Andrea M Burden7, Lars Englberger11, Roland Backhaus12, Andreas Serra13, Markus Béchir6. 1. drugsafety.ch, Seestrasse 221, 8700, Küsnacht, Switzerland. rustefan@ethz.ch. 2. Institute of Internal Medicine and Nephrology, Clinic Hirslanden, Zurich, Switzerland. rustefan@ethz.ch. 3. Center for Internal Medicine, Clinic Hirslanden, Aarau, Switzerland. rustefan@ethz.ch. 4. Pharmaceutical Sciences, Swiss Federal Institute of Technology Zurich (ETHZ), Zurich, Switzerland. rustefan@ethz.ch. 5. drugsafety.ch, Seestrasse 221, 8700, Küsnacht, Switzerland. 6. Center for Internal Medicine, Clinic Hirslanden, Aarau, Switzerland. 7. Pharmaceutical Sciences, Swiss Federal Institute of Technology Zurich (ETHZ), Zurich, Switzerland. 8. Hospital Pharmacy, Clinic Hirslanden, Zurich, Switzerland. 9. INTLAB AG, Zurich, Switzerland. 10. Labor Risch, Mocelular Genetics, Berne, Switzerland. 11. Cardiac Surgery, Clinic Hirslanden, Aarau, Switzerland. 12. Stroke Center and Clinic for Neurology, Clinic Hirslanden, Zurich, Switzerland. 13. Institute of Internal Medicine and Nephrology, Clinic Hirslanden, Zurich, Switzerland.
Abstract
PURPOSE: The antiplatelet prodrug clopidogrel is bioactivated by the polymorphic enzyme CYP2C19. Prospective clinical studies demonstrated an association between CYP2C19 loss of function (LoF) variants and an increased risk of thrombotic events under clopidogrel, but pharmacogenetic (PGx) testing is not frequently implemented in clinical practice. We report our experience with PGx-guided clopidogrel therapy with particular regard to clinically relevant patient management changes. METHODS: We conducted an observational study analyzing patients that underwent PGx testing for clopidogrel therapy at two Swiss hospitals. Primary outcome was the proportion of patients with clinically relevant PGx-based management recommendations and their implementation. The association of recurrent ischemic events under clopidogrel with CYP2C19 LoF variants and other factors was explored in a multivariate case-control analysis. RESULTS: Among 56 patients undergoing PGx testing, 18 (32.1%) were classified as CYP2C19 intermediate or poor metabolizers. This resulted in 17 recommendations for a change of antiplatelet therapy, which were implemented in 12 patients (70.1%). In the remaining five patients, specific reasons for non-implementation could be identified. Recurrent ischemic events under clopidogrel were associated with LoF variants (OR 2.2, 95% CI 0.3-14.4) and several cardiovascular risk factors. Associations were not statistically significant in our small study, but plausible and in line with estimates from large prospective studies. CONCLUSION: PGx-guided clopidogrel therapy can identify patients with an elevated risk of ischemic events and offer evidence-based alternative treatments. Successful implementation in clinical practice requires a personalized interdisciplinary service that evaluates indications and additional risk factors, provides specific recommendations, and proactively follows their implementation.
PURPOSE: The antiplatelet prodrug clopidogrel is bioactivated by the polymorphic enzyme CYP2C19. Prospective clinical studies demonstrated an association between CYP2C19 loss of function (LoF) variants and an increased risk of thrombotic events under clopidogrel, but pharmacogenetic (PGx) testing is not frequently implemented in clinical practice. We report our experience with PGx-guided clopidogrel therapy with particular regard to clinically relevant patient management changes. METHODS: We conducted an observational study analyzing patients that underwent PGx testing for clopidogrel therapy at two Swiss hospitals. Primary outcome was the proportion of patients with clinically relevant PGx-based management recommendations and their implementation. The association of recurrent ischemic events under clopidogrel with CYP2C19 LoF variants and other factors was explored in a multivariate case-control analysis. RESULTS: Among 56 patients undergoing PGx testing, 18 (32.1%) were classified as CYP2C19 intermediate or poor metabolizers. This resulted in 17 recommendations for a change of antiplatelet therapy, which were implemented in 12 patients (70.1%). In the remaining five patients, specific reasons for non-implementation could be identified. Recurrent ischemic events under clopidogrel were associated with LoF variants (OR 2.2, 95% CI 0.3-14.4) and several cardiovascular risk factors. Associations were not statistically significant in our small study, but plausible and in line with estimates from large prospective studies. CONCLUSION:PGx-guided clopidogrel therapy can identify patients with an elevated risk of ischemic events and offer evidence-based alternative treatments. Successful implementation in clinical practice requires a personalized interdisciplinary service that evaluates indications and additional risk factors, provides specific recommendations, and proactively follows their implementation.
Authors: Daniel M F Claassens; Gerrit J A Vos; Thomas O Bergmeijer; Renicus S Hermanides; Arnoud W J van 't Hof; Pim van der Harst; Emanuele Barbato; Carmine Morisco; Richard M Tjon Joe Gin; Folkert W Asselbergs; Arend Mosterd; Jean-Paul R Herrman; Willem J M Dewilde; Paul W A Janssen; Johannes C Kelder; Maarten J Postma; Anthonius de Boer; Cornelis Boersma; Vera H M Deneer; Jurriën M Ten Berg Journal: N Engl J Med Date: 2019-09-03 Impact factor: 91.245
Authors: Dirk Sibbing; Daniel Aradi; Dimitrios Alexopoulos; Jurrien Ten Berg; Deepak L Bhatt; Laurent Bonello; Jean-Philippe Collet; Thomas Cuisset; Francesco Franchi; Lisa Gross; Paul Gurbel; Young-Hoon Jeong; Roxana Mehran; David J Moliterno; Franz-Josef Neumann; Naveen L Pereira; Matthew J Price; Marc S Sabatine; Derek Y F So; Gregg W Stone; Robert F Storey; Udaya Tantry; Dietmar Trenk; Marco Valgimigli; Ron Waksman; Dominick J Angiolillo Journal: JACC Cardiovasc Interv Date: 2019-06-12 Impact factor: 11.195
Authors: S A Scott; K Sangkuhl; E E Gardner; C M Stein; J-S Hulot; J A Johnson; D M Roden; T E Klein; A R Shuldiner Journal: Clin Pharmacol Ther Date: 2011-06-29 Impact factor: 6.875
Authors: Naveen L Pereira; Charanjit S Rihal; Derek Y F So; Yves Rosenberg; Ryan J Lennon; Verghese Mathew; Shaun G Goodman; Richard M Weinshilboum; Liewei Wang; Linnea M Baudhuin; Amir Lerman; Ahmed Hasan; Erin Iturriaga; Yi-Ping Fu; Nancy Geller; Kent Bailey; Michael E Farkouh Journal: Circ Cardiovasc Interv Date: 2019-04 Impact factor: 6.546
Authors: S Claiborne Johnston; J Donald Easton; Mary Farrant; William Barsan; Robin A Conwit; Jordan J Elm; Anthony S Kim; Anne S Lindblad; Yuko Y Palesch Journal: N Engl J Med Date: 2018-05-16 Impact factor: 91.245
Authors: Tabassome Simon; Céline Verstuyft; Murielle Mary-Krause; Lina Quteineh; Elodie Drouet; Nicolas Méneveau; P Gabriel Steg; Jean Ferrières; Nicolas Danchin; Laurent Becquemont Journal: N Engl J Med Date: 2008-12-22 Impact factor: 91.245
Authors: Borja Ibanez; Stefan James; Stefan Agewall; Manuel J Antunes; Chiara Bucciarelli-Ducci; Héctor Bueno; Alida L P Caforio; Filippo Crea; John A Goudevenos; Sigrun Halvorsen; Gerhard Hindricks; Adnan Kastrati; Mattie J Lenzen; Eva Prescott; Marco Roffi; Marco Valgimigli; Christoph Varenhorst; Pascal Vranckx; Petr Widimský Journal: Eur Heart J Date: 2018-01-07 Impact factor: 29.983
Authors: Shu Huang; Seonkyeong Yang; Shirly Ly; Ryan H Yoo; Wei-Hsuan Lo-Ciganic; Michael T Eadon; Titus Schleyer; Elizabeth Whipple; Khoa Anh Nguyen Journal: Eur J Clin Pharmacol Date: 2022-06-03 Impact factor: 3.064
Authors: Luke C Pilling; Deniz Türkmen; Hannah Fullalove; Janice L Atkins; Joao Delgado; Chia-Ling Kuo; George A Kuchel; Luigi Ferrucci; Jack Bowden; Jane A H Masoli; David Melzer Journal: BMJ Open Date: 2021-12-13 Impact factor: 2.692